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    Key Statements
▶  The goal of early cancer detection 
is to recognise cancers as early 
as possible by means of simple, 
low-stress examinations in order 
to improve the patients’ chances 
of survival and reduce mortality 
in the general population due to 
cancer.
▶  A decrease in mortality has been 
observed in recent years with 
cancer of the colon and rectum, 
prostate gland and cervix.
▶  Newly introduced early detec-
tion measures can lead to a 
temporary increase in incidence 
(e. g. with skin and breast can-
cer).
▶  A significant reduction in the 
incidence of cervical cancer 
can be recognised since the in-
troduction of the Pap smear in 
the 1970s.
▶  To date, mammography screen-
ing is the only early detection 
programme in Germany in 
which invitations are extended 
in all parts of the country.
Epidemiology and Early Diagnosis of Common Cancers  
in Germany 
With the general increase in the life expectancy of populations, the importance 
of cancer is also increasing in Germany and in all other industrialised countries. 
Despite significant improvements in cancer patients’ chances of survival, the 
absolute number of annual deaths due to cancer has risen relatively continuously 
in the last 30 years. Due to the changed spectrum of the causes of death, every 
fourth death today is attributable to a form of cancer, as opposed to one in five 
deaths in 1980.
In addition to a reduction of the risk factors (primary prevention), such as 
tobacco consumption or certain infections, early cancer detection (secondary 
prevention) offers the chance of reducing the burden of disease in the general 
population. The early diagnosis measures (screening examinations) provided by 
the statutory health insurance funds in Germany currently apply to tumours of 
the skin, colon and rectum, the cervix and mammary gland with women and the 
prostate gland with men. They are free of charge for insured persons and are 
usually regulated via the directive on the early diagnosis of cancers issued by the 
Federal Joint Committee (G-BA 2011).
The objective of all early cancer detection (ECD) measures is to recognise can-
cers as early as possible by means of relatively simple, low-stress examinations in 
order to improve the success of the treatment and thereby the chances of survival 
of those affected by prescribing the suitable therapies. The actual screening exa-
mination often provides only suspicions which are then either substantiated or 
rejected in the course of more thorough examinations, such as a tissue sampling. 
With colorectal and cervical cancer in particular, a goal of early detection is the 
avoidance of invasive tumours which grow into and destroy the tissue through 
the recognition and treatment of preliminary stages of cancer (locally limited 
in-situ tumours).
The success of early cancer detection measures on the level of the general 
public depends on the quality of the procedures used and the manner in which 
they are conducted, as well as the willingness of each target group to participate. 
Fundamentally, however, early cancer detection also involves potential disadvan-
tages either through the risks of the examination itself (e. g. low radiation levels 
during the mammography to detect breast cancer) or the physical or emotional 
consequences of false positive findings and the unnecessary diagnostic exami-
nations this entails.
An »early cancer detection programme« (as defined by EU directives) is only 
said to exist when a certain organisational level has been reached with regard 
to screening, which must above all have a systematic invitation system and 
continuous quality assurance integrated into the programme. This programme 
characteristic has currently only been realised in Germany for mammography 
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screening of women aged between 50 and 69 years. The 
other early detection measures offered by the health insu-
rance funds free of charge do not involve a special invita-
tion process.
In the space of the last 10 years, early cancer detection 
has become more and more the focus of political and pub-
lic discussion. During the same period, there were com-
prehensive changes to the existing methods in Germany. 
Nationwide mammography screening was established 
in all federal states between 2005 and 2008. Other ECD 
services (colon and rectum and skin cancer) were either 
modified or expanded.
The further development of early cancer detection is also 
one of the main goals of the National Cancer Plan, in which 
politics and associations are currently involved in a concer-
ted action to improve the care of cancer patients (Federal 
Health Ministry (BMG) 2012).
When assessing the effects of early cancer detection on 
the level of the population in general, the epidemiologi-
cal cancer registries, which have been set up all over the 
country in all federal states since 2009, play a vital role. 
By linking the registry data with the participant cohorts, 
the rate of tumours detected outside the screening exa-
minations (interval carcinomas), which are an important 
quality indicator, can be determined on the one hand. In 
a similar manner, the death rate (mortality) attributable to 
cancer among the participants can be determined on the 
other hand and compared with the mortality rate among 
the entire population from the statistics on the causes of 
death. The data on the development of incidence (disease 
frequency) and tumour stage distribution also provide 
important information.
On a national government level, the data from the epi-
demiological cancer registries are regularly evaluated and 
published by the Centre for Cancer Registry Data (ZfKD) at 
the Robert Koch Institute.
For this reason, several important epidemiological para-
meters (see the box on P. 4) are presented in the following 
article on the cancer types for which the corresponding early 
detection services currently exist in Germany. In addition to 
the ZfKD data, the official statistics on the causes of death 
of the Federal Statistical Office were used along with exis-
ting results on the use of early detection services, some of 
which were taken from the telephonic health survey »Ger-
man Health Update« (GEDA) conducted by the Robert Koch 
Institute in 2010.
Center for Cancer Registry Data
The Centre for Cancer Registry Data (ZfKD) was set up at the 
Robert Koch Institute (RKI) in the Epidemiology and Health 
Reporting department after the Federal Cancer Registry Data 
Act (2009) came into effect in January 2010. The ZfKD eva-
luates on a national level the data on new cases of cancer 
in the population recorded regionally in the epidemiological 
(population-related) cancer registries of each federal state. 
As several cancer registries are still being set up, the data 
on the number of new cases and survival rates for Germany 
published by the ZfKD are still estimations, even though they 
are made in line with an increasingly more reliable database.
You will find more information on this on the internet at 
www.krebsdaten.rki.de.
Skin cancer
The measures for the early detection of all forms of skin 
cancer in the early cancer detection programme of the sta-
tutory health insurance funds in Germany were regulated 
anew in mid-2008. Since then, people of both sexes with 
compulsory health insurance aged 35 and over are entitled 
to a complete examination of their skin every two years by a 
physician (dermatologist, general practitioner etc.) with the 
requisite further training. In the years prior to this (from 
1970), physical examinations were not yet a part of the com-
plex preventive services offered.
With skin cancer, a difference is made between basal cell 
and cutaneous squamous cell carcinomas on the one hand 
and malignant melanomas of the skin on the other. Overall, 
skin cancer accounts for slightly more than 1 % of all deaths 
due to cancer in Germany (approx. 3,000 per year) with men 
and women. Of these, more than 80 % are attributable to 
malignant melanomas of the skin. In addition to this, people 
with malignant melanomas die an average of 10 years earlier 
than patients with basal cell and cutaneous squamous cell 
carcinomas (average age 71 as opposed to 82 years).
The proportion of malignant melanomas of the skin in all 
new cancer cases is roughly 4 %. Basal cell and cutaneous 
squamous cell carcinomas are much more common in Ger-
many where more than 150,000 new cases can be expected 
every year. As is customary all over the world, the Centre for 
Cancer Registry Data only estimates in detail the frequency of 
malignant melanomas of the skin (RKI, GEKID 2012).
As in other European countries too, the rate at which peo-
ple in Germany are diagnosed with malignant melanomas 
has been rising for decades. A sharp increase in incidence 
German Health Update (GEDA) 
Data owner: Robert Koch Institute
Goals:  Provision of updated data on 
health-related topics and the  
analysis of current developments 
and trends 
Survey method:  Computer-assisted telephone  
interviews (CATI)
Population:  People resident in Germany aged 18 
years and over
Sample:  22,050 women und men
Cooperation rate:  55.8 % 
Survey period:  September 2009 to Juli 2010
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was observed in 2008, the year in which intensified mea-
sures for the early detection of skin cancer were introduced 
(RKI, GEKID 2012).
With women aged up to 55, malignant melanomas of the 
skin are diagnosed much more frequently than with men 
of the same age, but this ratio is reversed after the age of 55 
(Figure 1). This means that with an median age of 60 years, 
women develop malignant skin melanomas earlier than 
men with an median age of 66.
The death rates for malignant skin melanomas are on 
roughly the same level with younger women and men. In 
contrast, however, considerably lower death rates are recor-
ded for women aged 50 and over than for men (Figure 2). 
Whereas the age-standardised death rates among women 
have decreased by roughly 10 % since 1980, they have 
risen by roughly 10 % among men over the same period. 
The lower mortality rates among women with malignant 
melanomas is possibly attributable to the fact that on ave-
rage, diagnosis is made earlier with prognostically more 
favourable tumour stages.
There is currently a very favourable relative 5-year survi-
val rate of 91 % for women with malignant melanomas of 
the skin in Germany, while at 87 %, this rate is only slightly 
worse for men. The tumour stage at which the melanoma 
is diagnosed makes it a major factor in this positive deve-
lopment of survival rates.
At least every second melanoma is discovered at an early 
tumour stage (T1) so that the chances of successful treat-
ment are good, with results once again being slightly bet-
ter for women. The results of the latest GEDA Study 2010 
show that women and men participate in equal measure 
Figure 1
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of action differ and these should be discussed with the 
attending physician. Cancer of the colon and rectum is 
the second most common form of cancer with both men 
and women. Roughly 30,000 women and 35,000 men 
contracted the disease in 2008. As is customary, the very 
rare tumour of the small intestine was not included in this 
morbidity group.
The most recent age-standardised incidence rates 
showed a slight decline with women. They remained sta-
ble with men, although there was an increase in absolute 
case numbers due to demographic changes (RKI, GEKID 
2012) (Figure 3).
In contrast to this, the age-standardised death rates have 
decreased by more than 20 % for both sexes in the last 
ten years. In 2008, roughly 3,000 fewer women died of 
colorectal cancer than in 1999, while the absolute number 
in the early detection programme for skin cancer that was 
introduced in 2008. Whereas participation among women 
of all ages is slightly higher, more frequent participation 
has been determined for men, especially the more elderly 
(Table 1) (GEDA 2012).
Indicators 
Incidence: 
disease frequency, disease rate: annual number of new cases 
per 100,000 persons
Mortality: 
Death rate; annual number of deaths per 100,000 persons
Age-specific rates: 
These show the connection between age and incidence or 
mortality. The age-specific incidence and mortality rates 
are given as annual rates per 100,000 persons in each age 
group. 
Age-standardised rates: 
Age standardisation allows the comparison of rates in 
populations with different age structures. It indicates the 
incidence or mortality among a total of 100,000 persons of 
a predetermined, usually fictitious, age structure. The so-
called Old European standard was used here.
Relative survival rates: 
Survival rates describe average survival chances. Relative 
survival takes into account the fact that only a certain per-
centage of the deaths among cancer patients are attributab-
le to cancer because a certain mortality rate among persons 
of the same age and sex has to be expected due to other 
underlying diseases. A relative 5-year survival rate of 80 %, 
for example, means that the percentage of cancer patients 
who still survive 5 years after the diagnosis equates to 80 % 
of the expected percentage of survivors from a population 
of the same age and sex without cancer.
Tumour stages: 
Tumour stages classify the size of a tumour and are a 
component of TNM classification in which the tumour size 
(T), affected lymph nodes (N) and occurrence of distant 
metastasis (M) are classified. TNM classification is used to 
describe the spread of a solid malignant tumour at the time 
of diagnosis. Tumour sizes are given in four stages (T-1 to 
T-4), with T-1 being the early stage and T-4 the late stage. 
Table 1
Participation in early skin cancer detection among respondents aged 35 
and over
Database: GEDA 2010
Single/Multiple participation in early skin cancer detection
% (95 %-CI)
Total 33.4 (32.4 – 34.3)
Total Women 32.9 (31.6 – 34.1)
Age group
35 to 44 34.2 (32.1 – 36.4)
45 to 54 33.5 (31.3 – 35.7)
55 to 64 34.9 (32.3 – 37.7)
65 and over 30.5 (28.1 – 33.1)
Total Men 33.9 (32.5 – 35.4)
Age group
35 to 44 27.5 (25.1 – 30.1)
45 to 54 30.4 (27.8 – 33.0)
55 to 64 32.3 (29.4 – 35.3)
65 and over 44.2 (41.1 – 47.3)
Cancer of the colon and rectum
Various examination methods for the early detection of 
cancer of the colon and rectum have been available for 
many years. People with statutory health insurance aged 
between 50 and 54 are entitled to an annual stool test 
(guaiac test / FOBT) for fecal occult blood. From the age 
of 55, the insured persons have the option of having an 
early detection colonoscopy performed (National Associa-
tion of SHI Physicians (KBV) 2012). Of all measures, the 
colonoscopy has the highest sensitivity and specificity for 
the detection of neoplasms in the colorectum (Schmiegel 
et al. 2008). During this examination, colon polyps from 
which potentially malignant tumours can develop can also 
be removed if necessary. If there are no conspicuous fin-
dings, there is an entitlement to a repeat colonoscopy after 
ten years.
If the offered colonoscopy is not used, insured peop-
le aged 55 and over can have a stool blood test conduc-
ted as an alternative every two years. If the findings are 
conspicuous here, the insured person is entitled to have 
them clarified per colonoscopy. For persons with a higher 
morbidity risk (family history of colorectal cancer, chronic 
intestinal inflammation etc.), the recommended courses 
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Prostate cancer
The early detection examination for prostate cancer is part of 
the early detection services of the statutory health insurance 
funds and currently comprises an annual examination of the 
external sexual organs and palpation of the prostate gland 
and related lymph nodes (digital-rectal examination, DRE) 
for men aged 45 and over.
The use of the blood test for prostate-specific antigens (PSA 
test) for the early detection of prostate cancer is still the sub-
ject of international debate (Andriole et al. 2009, Schröder 
et al. 2009, Sandblom et al. 2011) as it leads to over-diagnosis 
which involves unnecessary treatments. For this reason, the 
PSA test is not a component of statutory early detection in 
Germany. It has to be paid for by the patients themselves as 
an individual health service (IGel-Monitor 2012).
With 26 %, prostate cancer is the most common form of 
cancer among men in Germany and with 10 % the third most 
frequent cause of death from cancer. The number of new 
cases has risen steadily in recent years and reached approx. 
63,400 in 2008. This is also reflected in the age-standardised 
incidence rate, which has risen by almost 25 % since 1999 
(Figure 4) (RKI, GEKID 2012).
An increase can be recognised in particular in the age 
group between 50 and 74 (Figure 5), although the overall 
increase does not appear to have continued since roughly 
2003. Based on the latest population forecasts, which assume 
that the percentage of over 60-year-old men will almost dou-
ble in Germany by 2050, it can be expected that the absolute 
number of prostate cancer cases will also increase signifi-
cantly (DGU 2011).
In contrast to this, the age-standardised death rate has 
stayed on a relatively constant level over the years and has 
even shown a slight decline since 2003. This increase in the 
incidence rate with an unchanged death rate is attributable 
above all to increased use of the PSA test (RKI 2007) and can 
of deaths among men remained more or less constant 
(Figure 3). Around half of the people who contract the 
disease are still alive five years after the initial diagnosis. 
This makes colorectal cancer one of the cancer types with 
medium prognosis. As symptoms such as blood in the 
stool and pain usually only occur at a later stage, early 
detection takes on a special significance.
Information on the acceptance of colonoscopy by per-
sons aged 55 and over was collected in the GEDA Study 
2010, in which colonoscopies performed for reasons other 
than early detection (»curative colonoscopies«) were deli-
berately included. The results show that the percentage of 
persons who subject themselves to at least one colonosco-
py in the course of their life lies at roughly 58 % for both 
men and women. It can be seen here that a significant 
increase in participation is recorded for both sexes from 
the age of 65 (women approx. 60 %, men approx. 65 %) 
(Table 2) (RKI 2012).
The introduction of an organised invitation process, which 
has already enjoyed great success in other countries and 
within the scope of studies, is currently being discussed as 
the principal measure to increase the participation rate and 
thereby the early detection of colorectal cancer (BMG 2012).
Table 2
Use of colonoscopy (various reasons, including early detection)
Database: GEDA 2010
Single/Multiple participation in colonoscopy
% (95 %-CI)
Total 58.1 (56.6 – 59.6)
Total Women 57.5 (55.4 – 59.6)
Age group
55 to 64 53.0 (50.1 – 55.8)
65 and over 59.8 (57.0 – 62.5)
Total Men 58.9 (56.6 – 61.2)
Age group
55 to 64 50.0 (46.7 – 53.4)
65 and over 64.9 (61.8 – 67.8)
Figure 3
Absolute number of new cases and deaths from colorectal cancer (ICD-10: 
C18-21) in Germany 1999–2008 
Source: ZfKD
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themselves to at least one of the two examinations. Further 
analysis showed that participation in health checks in par-
ticular (e. g. Checkup 35) increases participation in ECD 
(Sieverding et al. 2008).
Cervical cancer (carcinoma of the cervix)
Within the scope of the early cancer detection schemes pro-
vided by the statutory health insurance funds, women in 
Germany aged 20 and over can have a cell smear of the 
cervix (PAP smear) carried out and evaluated once a year. 
In the vast majority of cases, cervical cancer is caused by 
a persistent infection with human papillomavirus (HPV).
For this reason, the German Standing Committee on 
Vaccination Recommendations (STIKO) recommended 
in March 2007 that all girls aged between 12 and 17 be 
vaccinated against two high-risk HPV types (HPV 16 and 
18), which are responsible for around 70 % of all cervical 
carcinomas. 
Despite this, the early detection smear test cannot be 
dispensed with because any changes to the cervix that have 
already occurred due to cancer cannot be prevented by 
the vaccination and infection with other HPV cannot be 
excluded. Since the introduction of the PAP smear test in 
the 1970s, a distinct decline in the incidence of cervical 
carcinomas and related mortality rate has been observed 
in Germany (RKI, GEKID 2012). 
In recent years, however, this decline has slowed down 
considerably and both rates have remained mainly stable 
since roughly 2003. The exceptions here are the figures 
for mortality among younger women aged 35 to 50 and 
older women over 65 years of age, both of which showed a 
further decline after the year 2000 (Figure 6).
The highest incidence rates for invasive carcinomas are 
currently with women aged 40 to 49. The median age at 
diagnosis is 53 and therefore significantly lower than for 
cancers in general (69 years). On average, women are diag-
nosed with carcinoma in-situ, the preliminary stage which 
be observed in practically all western industrialised coun-
tries. This is linked with a drop in the median age from 73 in 
1990 to 70 in 2008.
A representative population study of 11,778 men aged 
between 45 and 69 conducted in 2004 showed that almost 
two thirds of them had undergone the DRE test and almost 
half (46 %) had taken the DRE and PSA test. A third of 
those questioned, on the other hand, stated that they had 
never taken part in an early detection examination for 
prostate cancer (Sieverding et al. 2008). The percentage 
of non-participants is high in the younger age groups in 
particular, but it drops with increasing age with the result 
that roughly 80 % of 60 to 69 year-old men have subjected 
Figure 4
Age-standardised incidence and mortality rates for prostate cancer (ICD-
10: C61) in Germany 1999–2008 
Source: ZfKD
Figure 5
Age-specific incidence rates of prostate cancer (ICD-10: C61) in Germany 
Source: ZfKD 
per 100.000 inhabitants
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is easier to treat, at the age of only 36. Carcinoma in-situ 
is diagnosed up to four times more often than invasive 
carcinomas. The early cancer detection programme of the 
statutory health insurance funds focuses in particular on 
the diagnosis and timely removal of preliminary stages of 
cervical cancer, the last stage of which is the carcinoma in-
situ before the invasive carcinoma forms.
In contrast to mammography screening, women in the 
stipulated age group in Germany are not invited to early 
detection examinations for cervical cancer but despite this, 
many women make use of this early detection measure. A 
special evaluation of the years 2002 to 2004 conducted by 
the Central Research Institute of Ambulatory Health Care 
(Association of SHI Physicians North-Rhine and Bremen) 
showed that the participation rate among under 50-year-
olds lies between 70 % and 80 % within a period of three 
years and more than 60 % of women aged under 65 make 
use of the offer (Table 3) (Kerek-Bodden et al. 2009).
Different recommendations are given in European gui-
delines, above all with regard to the examination interval 
and quality assurance. This has given good reason to think 
about further development in the early detection concept for 
cervical cancer within the scope of the National Cancer Plan 
(BMG 2012).
Breast cancer
Mammography screening was introduced in Germany’s 
federal states between 2005 and 2008 following a Bundes-
tag resolution from 2002 and the programme can be said to 
provide nationwide coverage since 2009. This makes it the 
first early detection measure in Germany with a programme 
character. Women aged between 50 and 69 receive a written 
invitation to participate in a standardised screening pro-
gramme with extensive quality assurance measures every 
two years.
The prime objective of the programme is to reduce the 
breast cancer mortality rate in each affected age group. 
According to the results of controlled studies conducted in 
the 1980s and 1990s in Scandinavia and the UK (Anderson 
et al. 1988, Tabar et al. 1989, Roberts et al. 1990), a reduction 
of 20 % to 30 % appears to be possible, which would mean 
as many as 2,000 prevented deaths in Germany every year.
Another goal is to reduce the frequency of stressful thera-
py procedures (radical mastectomy, chemotherapy), which 
are usually necessary at advanced stages and which involve 
Figure 6
Age-specific mortality due to cervical cancer (ICD-10: C53) in Germany 
Source: ZfKD
Table 3
Participation in early cervical cancer detection within a 3-year period 
(2002–2004)
Source: Kerek-Bodden et al. 2009
Participation in early cervical cancer detection
Age group %
20 to 24 79.0
25 to 29 81.1
30 to 34 79.3
35 to 39 76.7
40 to 44 73.5
45 to 49 71.7
50 to 54 69.2
55 to 59 65.7
60 to 64 61.7
65 to 69 54.4
70 to 74 42.2
75 to 79 31.3
80 and over 16.3
Age group
    15–34            35–39          40–44          45–49          50–54          55–59           60–64         65–69          70–74          75–79          80–84           85+
19801970
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considerable side-effects, and enable the use of more gentle 
forms of treatment by recognising tumours at an early stage.
Possible disadvantages of the procedure are summarised 
under the catchwords »over-therapy« or »over-diagnosis«, 
implying that the regular examination of clinically healthy 
women would probably lead to a large number of tumours 
being detected and treated which would not otherwise have 
troubled the women in question due to the long growth 
period of the tumour. International estimates of the extent 
of this effect lie far apart (Jorgensen et al. 2009, Puliti et al. 
2009, Kalager et al. 2012).
Whereas the effects of the programme on breast cancer 
mortality nationwide will probably only become apparent 
in 2015, the first effects on diagnosis rates can already be 
observed along with developments in the participation rate. 
Due to the restricted age group in the screening program-
me, the development of the age-specific incidence rates is 
of particular interest here (Figure 7).
Since 2005, the rate has increased by 16 % in the 50 to 59 
year-old age group and by 31 % with the 60 to 69 year-olds. 
Although a slight increase of roughly 5 % was recognised 
over the same period in all other age groups not directly 
affected by screening, the trends from the years prior to 
2005 have basically continued.
Thanks to systematic mammography screening, a parti-
cularly good data basis is available compared to the cancer 
types outlined above. This is distinguished by a high level 
of registration completeness as well as the completeness 
of data on the tumour stage (> 90 %) in virtually all federal 
states.
In this way, in addition to general incidence rates, inci-
dences by the individual tumour stages (stage-specific 
incidence rates) can be estimated throughout the country 
(Figure 8). A distinct increase in the incidence rate for T1 
tumours (< 2 cm) can be recognised here. Whereas the 
morbidity rates for T2 and T3 tumours remain stable, a 
slight but continuous reduction which set in before scree-
ning was introduced can be recognised with T4 tumours.
The participation rates (percentage of participants from 
all women invited) in the mammography screening pro-
gramme remained stable in the first few years at between 
50 % and 55 %, but it should be taken into account that due 
to the step-by-step build-up of the programme, the num-
ber of women invited every year increased step by step too 
between 2005 and 2008 (Kooperationsgemeinschaft Mam-
mographie 2011).
Overall, therefore, despite participation rates which 
have not been very high up to now, the first effects of orga-
nised mammography screening can be recognised in the 
nationwide data which at least prove that more smaller-
sized tumours were detected in each age group in the first 
screening phase than was previously the case. 
»Grey« screening (mammography examination after 
referral justified by unclear palpation findings or fami-
ly history), which was probably fairly widespread at the 
time, could possibly be responsible for the decline in T4 
tumours before 2005.
In the medium term, a more distinct reduction in the 
incidence of larger tumours (T2 to T4), in primary meta-
stasised cases and ultimately in the mortality rates in the 
age group between 50 and 74 would be an indication of the 
success of the programme (Fracheboud et al. 2004).
Figure 7
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Synopsis
Early cancer detection produces opportunities (reduced 
mortality rates, partially reduced incidence rates) as well 
as certain risks (»over-diagnosis«, »over-therapy«). If dia-
gnosed in time, the chances of success of the therapies 
prescribed for the cancer types discussed here, and there-
fore the chances of survival of the affected patients, can 
be very high. 
The anxiety caused by a false suspicion or prematu-
re diagnosis, however, and the potential consequences of 
what may in some cases be a superfluous therapy, can 
impair the patients’ quality of life.
Against this background, the methodical further deve-
lopment of early detection services on the one hand and the 
appropriate handling of available measures on the other are 
of key importance in the field of health policy.
Accordingly, more focus on European guidelines is the 
current goal within the scope of the National Cancer Plan 
(BMG 2012), which should result in the medium term in 
a higher level of organisation of the early detection of cer-
vical and colorectal cancer in Germany. 
It is planned to implement this in systematically orga-
nised, quality assured screening programmes. The provi-
sion of better information to insured persons regarding 
the benefits and risks of early cancer detection, as well as 
regular invitation letters to improve participation rates, 
should strengthen early detection.
In the long term, the concept of risk-adapted early detec-
tion is being considered for several cancer types (e. g. colo-
rectal and prostate cancer) in order to identify persons 
with a considerably higher risk on the basis of certain risk 
indicators (e. g. family history) and offer them suitable ear-
ly cancer detection measures (BMG 2012). More research 
is required here at the moment, however.
Dr. Klaus Kraywinkel, Dr. Joachim Bertz, 
Antje Laudi, Dr. Ute Wolf
Robert Koch Institute
 Centre for Cancer Registry Data,
Department of Epidemiology and
Health Reporting
Figure 8
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